BiotechTube
MPC Therapeutics

MPC Therapeutics

Geneva, Switzerland· Est.
mpc-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

MPC Therapeutics is pioneering a platform of metabolic enhancers to overcome key limitations in cell therapy, particularly CAR-T. Its core technology involves small molecules that reprogram T-cell mitochondria to boost stem cell memory populations, accelerate expansion, and improve anti-tumor efficacy. The company has transitioned to a commercial-stage entity with the launch of its first product, MitoStem™, and is backed by peer-reviewed data and industry recognition. Its business model focuses on providing these reagents as tools to cell therapy developers and manufacturers.

Oncology

Technology Platform

A mitochondrial reprogramming platform using small molecule reagents to metabolically enhance T cells ex vivo, biasing them towards stem cell memory phenotypes (Tscm) to improve durability, expansion, and anti-tumor efficacy in cell therapies.

Funding History

1
Total raised:$12M
Series A$12M

Opportunities

The massive and growing cell therapy market, plagued by high costs and variable efficacy, creates a strong demand for enabling technologies.
MPC's 'plug-and-play' reagents can be integrated across many developers' pipelines, offering a scalable business model less risky than developing a single therapeutic.
Success in improving outcomes for solid tumors, a major unmet need, could be a transformative value driver.

Risk Factors

Commercial success hinges on convincing cell therapy manufacturers to alter their established processes, a significant adoption barrier.
The platform's value requires continuous validation through partners' clinical trials, where any failure could impact MPC's reputation.
The company faces competition from other firms developing media, cytokines, and small molecules for cell culture optimization.

Competitive Landscape

MPC competes in the cell therapy tools and manufacturing optimization space. Direct competitors include companies developing alternative T-cell enhancers (e.g., cytokines like IL-7/IL-15, metabolic inhibitors), specialized culture media providers, and biotech firms with their own cell fitness platforms. Its differentiation lies in its specific focus on mitochondrial reprogramming to generate Tscm cells and its suite of traceable, process-ready reagents.

More companies in Switzerland →